AU2016282869B2 - Monoclonal anti-IL-1RAcP antibodies - Google Patents

Monoclonal anti-IL-1RAcP antibodies Download PDF

Info

Publication number
AU2016282869B2
AU2016282869B2 AU2016282869A AU2016282869A AU2016282869B2 AU 2016282869 B2 AU2016282869 B2 AU 2016282869B2 AU 2016282869 A AU2016282869 A AU 2016282869A AU 2016282869 A AU2016282869 A AU 2016282869A AU 2016282869 B2 AU2016282869 B2 AU 2016282869B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016282869A
Other languages
English (en)
Other versions
AU2016282869A1 (en
Inventor
Michael Brandt
Stephan Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Original Assignee
Sanofi Biotechnology SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS filed Critical Sanofi Biotechnology SAS
Publication of AU2016282869A1 publication Critical patent/AU2016282869A1/en
Assigned to Sanofi Biotechnology SAS reassignment Sanofi Biotechnology SAS Request for Assignment Assignors: MAB DISCOVERY GMBH
Application granted granted Critical
Publication of AU2016282869B2 publication Critical patent/AU2016282869B2/en
Priority to AU2022228107A priority Critical patent/AU2022228107A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2016282869A 2015-06-26 2016-06-23 Monoclonal anti-IL-1RAcP antibodies Active AU2016282869B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022228107A AU2022228107A1 (en) 2015-06-26 2022-09-06 Monoclonal anti-IL-1RACP antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15174184.0 2015-06-26
EP15174184 2015-06-26
EP15200772.0 2015-12-17
EP15200772 2015-12-17
PCT/EP2016/064588 WO2016207304A2 (en) 2015-06-26 2016-06-23 Monoclonal anti-il-1racp antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022228107A Division AU2022228107A1 (en) 2015-06-26 2022-09-06 Monoclonal anti-IL-1RACP antibodies

Publications (2)

Publication Number Publication Date
AU2016282869A1 AU2016282869A1 (en) 2018-01-18
AU2016282869B2 true AU2016282869B2 (en) 2022-08-18

Family

ID=56561339

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016282869A Active AU2016282869B2 (en) 2015-06-26 2016-06-23 Monoclonal anti-IL-1RAcP antibodies
AU2022228107A Abandoned AU2022228107A1 (en) 2015-06-26 2022-09-06 Monoclonal anti-IL-1RACP antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022228107A Abandoned AU2022228107A1 (en) 2015-06-26 2022-09-06 Monoclonal anti-IL-1RACP antibodies

Country Status (7)

Country Link
US (4) US10906971B2 (enExample)
EP (2) EP3960765A1 (enExample)
JP (3) JP7114460B2 (enExample)
CN (2) CN108026172B (enExample)
AU (2) AU2016282869B2 (enExample)
CA (1) CA2990305A1 (enExample)
WO (1) WO2016207304A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP2665749B1 (en) 2011-01-19 2016-01-13 Cantargia AB Anti-il1rap antibodies and their use for treating solid tumours
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
CN107109494B (zh) 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
SG11201703767XA (en) 2014-11-10 2017-06-29 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
EP3849608B1 (en) * 2018-09-13 2023-08-30 The Board of Regents of The University of Texas System Novel lilrb4 antibodies and uses thereof
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
WO2020261097A1 (en) * 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
TW202144410A (zh) 2020-03-13 2021-12-01 美商建南德克公司 抗介白素－３３抗體及其用途
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
CN111500668B (zh) * 2020-06-29 2020-09-25 南京诺艾新生物技术有限公司 一种用于测定人IL-36/IL36R/IL1RAcP通路抑制剂的生物学活性的方法
MX2023002901A (es) 2020-09-14 2023-06-01 Ichnos Sciences SA Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos.
IL303922A (en) 2020-12-23 2023-08-01 Cantargia Ab Anti-il1rap antibody
US20220411517A1 (en) 2021-05-21 2022-12-29 Leo Pharma A/S IL-1 Receptor Accessory Protein Inhibitors and Uses Thereof
CN115433278A (zh) * 2021-06-05 2022-12-06 苏州缔码生物科技有限公司 结合cs1蛋白兔重组单克隆抗体及应用
CN113956355B (zh) * 2021-07-26 2023-06-23 无锡傲锐东源生物科技有限公司 抗人脑利钠肽(bnp)兔单克隆抗体及其应用
CN116333139A (zh) * 2021-12-22 2023-06-27 上海复旦张江生物医药股份有限公司 一种抗fda0128抗体、其制备方法和应用
KR20250060305A (ko) 2022-09-21 2025-05-07 사노피 바이오테크놀로지 인간화 항-il-1r3 항체 및 사용 방법
WO2025043244A1 (en) * 2023-08-24 2025-02-27 Arizona Board Of Regents On Behalf Of Arizona State University Tandem antigen capture assays for measuring qsox1 isoforms
CN118255885B (zh) * 2024-04-24 2024-10-08 武汉爱博泰克生物科技有限公司 针对人瘦素的单克隆抗体、抗体对和检测试剂盒及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014113433A1 (en) * 2013-01-16 2014-07-24 George Mason University Binding domain mapping

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
EP0488470B1 (en) 1990-11-26 1997-05-28 Akzo Nobel N.V. Method for the production of antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
PE64396A1 (es) * 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6280955B1 (en) 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2002064630A2 (en) 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
JP2005509597A (ja) * 2001-08-07 2005-04-14 イミュネックス・コーポレーション 疾患の治療におけるインターロイキン−１受容体
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
DK2213685T3 (en) 2002-09-06 2014-03-03 Medarex Llc Therapeutic anti-IL-1R1 monoclonal antibody
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
PL224787B1 (pl) 2003-01-22 2017-01-31 Roche Glycart Ag Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SG143252A1 (en) 2003-10-09 2008-06-27 Ambrx Inc Polymer derivatives
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
JP2007522118A (ja) 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
PL2471813T3 (pl) 2004-07-15 2015-09-30 Xencor Inc Zoptymalizowane warianty Fc
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2007003041A1 (en) 2005-07-01 2007-01-11 John Schrader Methods of isolating cells and generating monoclonal antibodies
TWI478940B (zh) 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
CN101600793B (zh) 2006-05-19 2013-06-26 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
EP2271673B1 (en) 2008-03-26 2016-02-24 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
JP6141018B2 (ja) * 2009-12-24 2017-06-07 バイオマリン テクノロジーズ ベー．フェー． 炎症性障害を治療するための分子
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2400298B1 (en) 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
EP2665749B1 (en) 2011-01-19 2016-01-13 Cantargia AB Anti-il1rap antibodies and their use for treating solid tumours
MX354359B (es) * 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2013023015A2 (en) 2011-08-11 2013-02-14 Albert Einstein College Of Medicine Of Yeshiva University Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
US20150315279A1 (en) * 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US20150315179A1 (en) 2014-05-02 2015-11-05 Torrey Pines Institute For Molecular Studies Compounds and methods of treating neurological disorders
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
KR20250060305A (ko) 2022-09-21 2025-05-07 사노피 바이오테크놀로지 인간화 항-il-1r3 항체 및 사용 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014113433A1 (en) * 2013-01-16 2014-07-24 George Mason University Binding domain mapping

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALI SHAFAQAT ET AL, NATIONAL ACADEMY OF SCIENCES. PROCEEDINGS, NATIONAL ACADEMY OF SCIENCES, UNITED STATES, (2007-11-20), vol. 104, no. 47, pages 18660 - 18665 *
C. A. DINARELLO, "Interleukin-1 in the pathogenesis and treatment of inflammatory diseases", BLOOD, (2011-04-07), vol. 117, no. 14, doi:10.1182/blood-2010-07-273417, ISSN 0006-4971, pages 3720 - 3732 *
TOWNE JENNIFER E ET AL,JOURNAL OF BIOLOGICAL CHEMISTRY (2004-04-02), vol. 279, no. 14, pages 13677 - 13688 *

Also Published As

Publication number Publication date
US11198728B2 (en) 2021-12-14
WO2016207304A8 (en) 2017-04-20
US12240898B2 (en) 2025-03-04
CN115505042A (zh) 2022-12-23
CN108026172A (zh) 2018-05-11
WO2016207304A2 (en) 2016-12-29
US10906971B2 (en) 2021-02-02
CN108026172B (zh) 2022-04-29
US20190106487A1 (en) 2019-04-11
US20250154245A1 (en) 2025-05-15
JP7587549B2 (ja) 2024-11-20
JP2022106950A (ja) 2022-07-20
US20200407438A1 (en) 2020-12-31
AU2022228107A1 (en) 2022-09-29
EP3960765A1 (en) 2022-03-02
WO2016207304A3 (en) 2017-02-09
US20220169718A1 (en) 2022-06-02
JP7114460B2 (ja) 2022-08-08
EP3313887A2 (en) 2018-05-02
CA2990305A1 (en) 2016-12-29
JP2024153701A (ja) 2024-10-29
AU2016282869A1 (en) 2018-01-18
JP2018519364A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
US12240898B2 (en) Monoclonal anti-IL-1RAcP antibodies
US12024564B2 (en) Humanized anti-IL-1R3 antibodies
RU2753493C2 (ru) Анти-ох40 антитела и их применение
US11352432B2 (en) Antibodies specifically binding to human IL-1R7
EP3241847A1 (en) Her-2 binding antibodies
HK40069979A (en) Monoclonal anti-il-1racp antibodies
HK40116833A (en) Humanized anti-il-1r3 antibodies
EA049751B1 (ru) Гуманизированные анти-il-1r3 антитела
EA040391B1 (ru) Гуманизированные анти-il-1r3 антитела

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI BIOTECHNOLOGY SAS

Free format text: FORMER APPLICANT(S): MAB DISCOVERY GMBH

FGA Letters patent sealed or granted (standard patent)